TY - JOUR
T1 - Obesity promotes breast epithelium DNA damage in women carrying a germline mutation in BRCA1 or BRCA2
AU - Bhardwaj, Priya
AU - Iyengar, Neil M.
AU - Zahid, Heba
AU - Carter, Katharine M.
AU - Byun, Dong Jun
AU - Choi, Man Ho
AU - Sun, Qi
AU - Savenkov, Oleksandr
AU - Louka, Charalambia
AU - Liu, Catherine
AU - Piloco, Phoebe
AU - Acosta, Monica
AU - Bareja, Rohan
AU - Elemento, Olivier
AU - Foronda, Miguel
AU - Dow, Lukas E.
AU - Oshchepkova, Sofya
AU - Giri, Dilip D.
AU - Pollak, Michael
AU - Zhou, Xi Kathy
AU - Hopkins, Benjamin D.
AU - Laughney, Ashley M.
AU - Frey, Melissa K.
AU - Ellenson, Lora Hedrick
AU - Morrow, Monica
AU - Spector, Jason A.
AU - Cantley, Lewis C.
AU - Brown, Kristy A.
N1 - Publisher Copyright:
Copyright © 2023 The Authors, some rights reserved.
PY - 2023/2/22
Y1 - 2023/2/22
N2 - Obesity, defined as a body mass index (BMI) ≥ 30, is an established risk factor for breast cancer among women in the general population after menopause. Whether elevated BMI is a risk factor for women with a germline mutation in BRCA1 or BRCA2 is less clear because of inconsistent findings from epidemiological studies and a lack of mechanistic studies in this population. Here, we show that DNA damage in normal breast epithelia of women carrying a BRCA mutation is positively correlated with BMI and with biomarkers of metabolic dysfunction. In addition, RNA sequencing showed obesity-associated alterations to the breast adipose microenvironment of BRCA mutation carriers, including activation of estrogen biosynthesis, which affected neighboring breast epithelial cells. In breast tissue explants cultured from women carrying a BRCA mutation, we found that blockade of estrogen biosynthesis or estrogen receptor activity decreased DNA damage. Additional obesity-associated factors, including leptin and insulin, increased DNA damage in human BRCA heterozygous epithelial cells, and inhibiting the signaling of these factors with a leptin-neutralizing antibody or PI3K inhibitor, respectively, decreased DNA damage. Furthermore, we show that increased adiposity was associated with mammary gland DNA damage and increased penetrance of mammary tumors in Brca1+/− mice. Overall, our results provide mechanistic evidence in support of a link between elevated BMI and breast cancer development in BRCA mutation carriers. This suggests that maintaining a lower body weight or pharmacologically targeting estrogen or metabolic dysfunction may reduce the risk of breast cancer in this population.
AB - Obesity, defined as a body mass index (BMI) ≥ 30, is an established risk factor for breast cancer among women in the general population after menopause. Whether elevated BMI is a risk factor for women with a germline mutation in BRCA1 or BRCA2 is less clear because of inconsistent findings from epidemiological studies and a lack of mechanistic studies in this population. Here, we show that DNA damage in normal breast epithelia of women carrying a BRCA mutation is positively correlated with BMI and with biomarkers of metabolic dysfunction. In addition, RNA sequencing showed obesity-associated alterations to the breast adipose microenvironment of BRCA mutation carriers, including activation of estrogen biosynthesis, which affected neighboring breast epithelial cells. In breast tissue explants cultured from women carrying a BRCA mutation, we found that blockade of estrogen biosynthesis or estrogen receptor activity decreased DNA damage. Additional obesity-associated factors, including leptin and insulin, increased DNA damage in human BRCA heterozygous epithelial cells, and inhibiting the signaling of these factors with a leptin-neutralizing antibody or PI3K inhibitor, respectively, decreased DNA damage. Furthermore, we show that increased adiposity was associated with mammary gland DNA damage and increased penetrance of mammary tumors in Brca1+/− mice. Overall, our results provide mechanistic evidence in support of a link between elevated BMI and breast cancer development in BRCA mutation carriers. This suggests that maintaining a lower body weight or pharmacologically targeting estrogen or metabolic dysfunction may reduce the risk of breast cancer in this population.
UR - http://www.scopus.com/inward/record.url?scp=85148551082&partnerID=8YFLogxK
U2 - 10.1126/scitranslmed.ade1857
DO - 10.1126/scitranslmed.ade1857
M3 - Article
C2 - 36812344
AN - SCOPUS:85148551082
SN - 1946-6234
VL - 15
JO - Science Translational Medicine
JF - Science Translational Medicine
IS - 684
M1 - eade1857
ER -